TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00578305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as a sterile liquid in single-use vials for iv administration.
Study: NCT00578305
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00578305
Drug: Folic acid or folate
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00313209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT03188185
Drug: ALKS 5461 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, administered sublingually
Study: NCT01179516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine placebo-matching capsules
Study: NCT04338074
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets p.o. three times per day x 5 days
Study: NCT01409135
Drug: ASG-22CE
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT00980200
Drug: Dose 4 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD once daily
Study: NCT00980200
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00980200
Drug: Dose 2 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD once daily
Study: NCT02085603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01535573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg per day for 9 weeks
Study: NCT03746704
Drug: 89Zr˗DFO˗REGN3504
Approvals — FDA: no, EMA: no, PMDA: no
Description: 89Zr˗DFO˗REGN3504
Study: NCT03854708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution) was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. The placebo consists of a 0.9 % saline solution containing 5 % albumin.
Study: NCT02889380
Drug: No Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
Study: NCT00153530
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. chemotherapy with radiotherapy~2. chemotherapy without radiotherapy
Study: NCT01528163
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
Study: NCT02042781
Drug: PG545
Normalized name: Heparan Sulfate Mimetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG545 will be administered once weekly, as a one hour IV infusion. Patients will be treated until they exhibit disease progression, withdraw due to poor tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 250 mg anticipated.
Study: NCT03615183
Drug: MK-8527
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral capsule
Study: NCT02135692
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
Study: NCT04012047
Drug: Levcromakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Study: NCT01172145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
Study: NCT01600469
Drug: DAOI-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-1500 mg/day, oral, for 24 weeks
Study: NCT04134091
Drug: LPCN 1144 Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as 225 mg testosterone undecanoate + 238 mg d-alpha tocopherol BID
Study: NCT04134091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral matching placebo capsule administered as BID
Study: NCT04991194
Drug: BIA 5-1058
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours \[Day (D)2 to D9\] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.
Study: NCT01218607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken twice daily for 16 weeks
Study: NCT03525522
Drug: Topical corticosteroid Diprosone
Normalized name: Diprolene Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of topical corticosteroids Diprosone
Study: NCT00539110
Drug: zolipidem
Approvals — FDA: no, EMA: no, PMDA: no
Description: zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
Study: NCT01982292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
Study: NCT01111045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04320238
Drug: thymosin alpha 1
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: thymosin alpha 1 subcutaneous injection 1 time per week.
Study: NCT01069822
Drug: AZD6765
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV solution
Study: NCT02249650
Drug: TSB-9-W1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
Study: NCT06558916
Drug: Dexketoprofen Trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06558916
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.
Study: NCT00833586
Drug: Lamisil® 250 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 250 mg
Study: NCT00838279
Drug: Lamictal® 25 mg Chewable Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 25 mg, single-dose fasting
Study: NCT01318993
Drug: GSK1605786A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 milligrams twice daily
Study: NCT01733472
Drug: GA-arm, remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm
Study: NCT02646982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matched placebo will be given once daily for 12 months.
Study: NCT02830880
Drug: FACBC PET-CT
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.
Study: NCT01671852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01464476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo. Once daily, oral administration
Study: NCT00304187
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
Study: NCT00304187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 250 mg or 500 mg, three times a day for 6 weeks
Study: NCT01929863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)
Study: NCT00185458
Drug: LNG IUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
Study: NCT00906399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
Study: NCT04437199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.
Study: NCT01457807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered with the same intervention scheme as intervention 1 and 2
Study: NCT01457807
Drug: AZD3241 Alternative titration scheme with formulation 1 or 2
Normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral dose bd on Day 1, 100 mg oral dose bd on Day 2 and 3, 200 mg oral dose bd on Day 4, 300 mg oral dose bd on Day 5 to 7 and 300 mg once in the morning on Day 8
Study: NCT02965495
Drug: YYD302 2ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYD302 2ml
Study: NCT02965495
Drug: YYD302 3ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYD302 3ml
Study: NCT00073307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02965495
Drug: Placebo 3ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: phosphate buffered saline 3ml
Study: NCT03776175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.
Study: NCT02344888
Drug: Clomiphene citrate and Prednisolone
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
Study: NCT02344888
Drug: Clomiphene citrate and folic acid
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
Study: NCT02486198
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)
Study: NCT02486198
Drug: GM
Normalized name: IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)
Study: NCT04788355
Drug: Control group (standard hospital treatment)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications defined by the hospital involved in the study
Study: NCT00421668
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: zinc
Study: NCT00421668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02137564
Drug: gamma secretase inhibitor PF-03084014
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01784965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
Study: NCT01362036
Drug: TXA127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
Study: NCT00840281
Drug: Cefzil® 500 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 500 mg, single-dose fasting
Study: NCT00076622
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
Study: NCT00076622
Drug: No antidepressant medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants assigned to discontinue current medication (no antidepressant medication) will be monitored over a period of one year for recurrence of depression and related symptoms.
Study: NCT00685477
Drug: Experimental Sequence ACB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
Study: NCT00685477
Drug: Experimental Sequence BCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
Study: NCT00685477
Drug: Experimental Sequence CBA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
Study: NCT01240460
Drug: XL147 (SAR245408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as 100-mg, 150-mg and/or 200-mg tablets
Study: NCT01731652
Drug: TMX-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03693677
Drug: 5-FU/LV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
Study: NCT00003683
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01422291
Drug: Paracetamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gr
Study: NCT01662895
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
Study: NCT02973737
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg once daily
Study: NCT02973737
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 per day on day 1 through 14, every 21 days.
Study: NCT04049045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
Study: NCT00522587
Drug: Fixed remifentanil dose 1
Normalized name: remifentanil 1 MG
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 1 of remifentanil
Study: NCT00522587
Drug: Fixed remifentanil dose 2
Normalized name: remifentanil 2 MG
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 2 of remifentanil
Study: NCT00522587
Drug: Fixed remifentanil dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 3 of remifentanil
Study: NCT00522587
Drug: Fixed remifentanil dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 4 of remifentanil
Study: NCT00522587
Drug: Fixed remifentanil dose 5
Normalized name: remifentanil 5 MG
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 5 of remifentanil
Study: NCT00522587
Drug: Fixed remifentanil dose 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 6 of remifentanil
Study: NCT03106623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Placebo once a daily for 4 weeks
Study: NCT02115204
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02115204
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01937234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.~Maximum of 3 doses.
Study: NCT03017170
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
Study: NCT01838681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, tablets, orally
Study: NCT01838681
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
Study: NCT00491192
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02067611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parallel Assignment
Study: NCT03897621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).
Study: NCT02417298
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
Study: NCT03757910
Drug: 18F-MK-6240
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: This radiotracer will be used to detect Tau.The injected activity will equal 5 millicuries (mCi).
Study: NCT01462279
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
Study: NCT03861247
Drug: Phosphate-binder intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .
Study: NCT03257865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally daily for 3 weeks.
Study: NCT01606111
Drug: 0.9% NaCl, saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
Study: NCT02795832
Drug: ZPL-5212372 1% w/w Ointment BID
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02795832
Drug: Placebo Ointment BID
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03543410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (supplied in two tablets/day)
Study: NCT00666926
Drug: PF00562271
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg twice daily \[BID\] with food, tablet
Study: NCT00666926
Drug: PF00562271
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg BID with food, tablet
Study: NCT02435914
Drug: AGN-223575 ophthalmic solution
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-223575 ophthalmic solution once or twice daily
Study: NCT02435914
Drug: AGN-223575 vehicle ophthalmic solution
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle to AGN22375 ophthalmic solution once or twice daily.
Study: NCT02090400
Drug: Calcium/Vit D
Normalized name: calcium/vit D3/mag/folic ac/K1 500 mg-100 unit-45 mg-800 mcg-40 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg / 400 IU Vit D
Study: NCT01908660
Drug: antiretroviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
Study: NCT03090568
Drug: BIA 5-453
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
Study: NCT01414153
Drug: 4.0 mg iSONEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg iSONEP given monthly intravitreously for 4 months
Study: NCT00533442
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part of standard maintenance
Study: NCT01539590
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
Study: NCT01414153
Drug: 0.5 mg iSONEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg iSONEP given monthly intravitreously for 4 months